The recent advances in genomics have proved to be linked to prognosis and response to therapy, for instance BRAF inhibitors have changed the landscape of BRAF V600 E mutant melanomas[14, 15], and ALK inhibitors have dramatically changed the outcome of EML4-ALK mutant lung cancer patients[16]. This evidence concerns the gene ALK and melanoma.